Gencurix
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Gencurix develops blood-based cancer diagnostic tests, products that detect cancer-related genetic changes from a small blood sample rather than a tissue biopsy, a technique known as liquid biopsy.
Its tests are used by hospitals and clinicians to guide treatment decisions for confirmed cancer patients, with a focus on breast and lung cancer, and it is also developing early-detection tests for liver and colorectal cancer. Listed on KOSDAQ, Korea's tech-focused small-cap board, the company's product portfolio centres on its GenesWell and Droplex test lines, several of which have received regulatory approval and national health-insurance coverage in Korea.
Summary is AI-generated and may contain errors · figures from DART filings
Its breast-cancer prognostic test, GenesWell BCT, was designated an innovative medical technology by Korea's National Evidence-based Healthcare Collaborating Agency (NECA).
Gencurix in five facts
What does Gencurix do?
Gencurix develops blood-based cancer diagnostic tests, products that detect cancer-related genetic changes from a small blood sample rather than a tissue biopsy, a technique known as liquid biopsy.
Where is Gencurix listed and in which sector?
Gencurix (Korean name: 젠큐릭스) trades under KRX code 229000 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Gencurix?
Its market capitalisation was US$34.6M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Gencurix's latest annual revenue and operating profit?
For fiscal year 2025, Gencurix reported revenue of US$5.7M, an operating loss of US$5M and a net loss of US$5.6M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 47.0% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Other market noticeOct 12
- [Amended] Material event report (business suspension)Oct 7
- Material event report (decision to redeem own convertible bonds early)
Gencurix decided on September 30, 2026 to acquire US$369K face value of its 8th-series convertible bonds before maturity from KB Securities (as trustee of the Alpha Plus Kosdaq Venture Mezzanine General Private Placement Trust No. 2) for US$376K, intending to retire the bonds after acquisition.
Capital raise · Sep 30 - [Amended] Material event report (merger)M&A · Sep 23 · 2 versions
- Report on securities held by executives/major shareholdersSep 18
- Report on securities held by executives/major shareholdersSep 18
- [Amended] Material event report (business suspension)Sep 18
- Other market noticeSep 16
- Other market noticeSep 15
- DisclosureSep 15
- Material event report (business suspension)Sep 15
- Exchange inquiry (rumor/report)Sep 14
- Trading suspensionSep 14
- Securities issuance results (voluntary)Sep 11
- Results of extraordinary shareholders' meetingSep 9
- [Attachment amended] Material event report (convertible bonds)Capital raise · Sep 3
- Material event report (convertible bonds)
Gencurix disclosed convertible bonds to raise US$369K, about 1.1% of its market value.
Capital raise · Sep 3 - Completion report on merger, etc. (merger)
Gencurix Co., Ltd. completed its merger with Genofix Co., Ltd. effective September 1, 2026 at a merger ratio of 1:5.3591461, issuing 742,456 new common shares to Genofix's shareholders; appraisal rights were not available as this was a small-scale merger, and all creditor objections were resolved.
M&A · Sep 1 - [Attachment amended] Material event report (merger)M&A · Jul 9
- [Amended] Completion report on merger, etc. (asset transfer)M&A · Jun 30
- [Attachment amended] Material event report (merger)M&A · Jun 26
- [Attachment amended] Material event report (merger)M&A · Jun 26
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)Earnings · Jan 29
- Operating results (preliminary) (fair disclosure)Earnings · Jan 16